Andrew Olaharski
Overview
Explore the profile of Andrew Olaharski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cadzow L, Brenneman J, Tobin E, Sullivan P, Nayak S, Ali J, et al.
Cancer Res
. 2024 Oct;
84(20):3419-3434.
PMID: 39402989
Defects in DNA repair pathways play a pivotal role in tumor evolution and resistance to therapy. At the same time, they create vulnerabilities that render tumors dependent on the remaining...
2.
Brooun A, Zhang J, Li C, Lam R, Cheng H, Shoemaker R, et al.
Toxicol Appl Pharmacol
. 2023 Jun;
474:116601.
PMID: 37321326
Two potent and selective KRAS inhibitors, ERAS-4693 and ERAS-5024, were generated as possible clinical candidates to treat patients harboring G12D mutations in solid tumors. Both molecules exhibited strong anti-tumor activity...
3.
Nagaraja R, Olaharski A, Narayanaswamy R, Mahoney C, Pirman D, Gross S, et al.
Toxicol Appl Pharmacol
. 2020 Jun;
401:115103.
PMID: 32522582
Small cell lung cancer (SCLC) is a particularly aggressive subset of lung cancer, and identification of new therapeutic options is of significant interest. We recently reported that SCLC cell lines...
4.
Popovici-Muller J, Lemieux R, Artin E, Saunders J, Salituro F, Travins J, et al.
ACS Med Chem Lett
. 2018 Apr;
9(4):300-305.
PMID: 29670690
Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells,...
5.
Colleton C, Brewster D, Chester A, Clarke D, Heining P, Olaharski A, et al.
Toxicol Pathol
. 2016 Mar;
44(3):458-66.
PMID: 27006130
The use of minipigs in preclinical safety testing of pharmaceuticals is considered an alternative to the more traditional dog and nonhuman primate (NHP) nonrodent species. Substantial evidence exists to suggest...
6.
Guan P, Olaharski A, Fielden M, Roome N, Dragan Y, Sina J
Expert Rev Clin Pharmacol
. 2014 Jan;
1(6):759-71.
PMID: 24410606
The screening of drug candidates to assess their carcinogenic potential has long been a challenge for drug development. While genotoxic compounds can be readily detected with a battery of standard...
7.
Fitzgerald K, Bergeron M, Willits C, Bowers S, Aubele D, Goldbach E, et al.
Toxicol Appl Pharmacol
. 2013 Mar;
269(1):1-7.
PMID: 23466428
Polo like kinase 2 (PLK2) phosphorylates α-synuclein and is considered a putative therapeutic target for Parkinson's disease. Several lines of evidence indicate that PLK2 is involved with proper centriole duplication...
8.
Fielden M, Adai A, Dunn 2nd R, Olaharski A, Searfoss G, Sina J, et al.
Toxicol Sci
. 2011 Aug;
124(1):54-74.
PMID: 21813463
Evaluating the risk of chemical carcinogenesis has long been a challenge owing to the protracted nature of the pathology and the limited translatability of animal models. Although numerous short-term in...
9.
Olaharski A, Albertini S, Kirchner S, Platz S, Uppal H, Lin H, et al.
Mutat Res
. 2008 Sep;
672(1):10-6.
PMID: 18812235
The GreenScreen GADD45alpha indicator assay has been assessed for its concordance with in vitro genotoxicity and rodent carcinogenicity bioassay data. To test robustness, sensitivity, and specificity of the assay, 91...